

SUPPLEMENTARY MATERIAL

Table S1: Advanced lipoprotein profile characteristics at baseline by treatment allocation.

	<i>Units</i>	<i>Control group</i>	<i>Intervention group</i>	<i>P value</i>
		<i>N=94</i>	<i>N=103</i>	
Cholesterol				
sdLDL	mmol/L	0.60 (0.53, 0.67)	0.60 (0.52, 0.68)	0.963
sdLDL /LDL	%	16.5 (14.7,18.3)	18.3 (15.9,20.8)	0.229
VLDL	mg/dL	31.9 (25.6, 38.2)	31.5 (25.3, 37.8)	0.932
IDL	mg/dL	17.4 (15.1, 19.8)	15.4 (13.0, 17.8)	0.210
Triglycerides				
VLDL	mg/dL	113 (91, 134)	112 (86, 138)	0.967
IDL	mg/dL	16.8 (14.9, 18.8)	15.6 (13.7, 17.6)	0.380
LDL	mg/dL	21.9 (19.4, 24.5)	20.0 (17.1, 22.9)	0.295
HDL	mg/dL	25.9 (20.8, 31.1)	25.7 (21.9, 29.6)	0.950
Particle number				
VLDL	nmol/L	89.4 (72.1, 106.8)	87.8 (68.3, 107.3)	0.894
IVLDL	nmol/L	2.10 (1.75, 2.44)	2.16 (1.80, 2.52)	0.806
mVLDL	nmolL	7.23 (5.65, 8.80)	7.64 (5.62, 9.66)	0.737
sVLDL	nmolL	80.1 (64.2, 96.0)	78.0 (60.6, 95.3)	0.850
IVLDL/VLDL	%	2.46 (2.28, 2.64)	2.60 (2.39, 2.80)	0.291
mVLDL/VLDL	%	8.29 (7.28, 9.29)	8.64 (7.68, 9.60)	0.597
sVLDL/VLDL	%	89.3 (88.3, 90.2)	88.8 (87.8, 89.7)	0.456
LDL	nmolL	1490 (1350, 1630)	1356 (1244, 1468)	0.130
ILDL	nmolL	178 (162, 194)	166 (149, 183)	0.303
mLDL	nmolL	411 (348, 474)	359 (305, 412)	0.199
sLDL	nmolL	901 (815, 987)	831 (770, 891)	0.178
ILDL/LDL	%	12.1 (11.3, 12.9)	12.3 (11.4, 13.1)	0.763
mLDL/LDL	%	27.2 (24.8, 29.5)	26.0 (23.7, 28.3)	0.449
sLDL/LDL	%	60.7 (58.0, 63.5)	61.7 (58.9, 64.6)	0.588
HDL	μmol/L	29.9 (26.9, 32.9)	29.6 (27.9, 31.2)	0.819
IHDL	μmol/L	0.31 (028, 0.33)	0.28 (0.26, 0.30)	0.099
mHDL	μmol/L	9.55 (8.63, 10.47)	8.89 (8.39, 9.40)	0.214
sHDL	μmol/L	20.1 (17.9, 22.2)	20.4 (18.8, 21.9)	0.820
IHDL/HDL	%	1.04 (0.97, 1.11)	0.96 (0.88, 1.05)	0.159
mHDL/HDL	%	32.1 (30.5, 33.6)	30.4 (28.3, 32.4)	0.167
sHDL/HDL	%	66.9 (65.3,68.5)	68.7 (66.5, 70.8)	0.162
Non-HDL	nmolL	1550 (1411, 1688)	1414 (1300, 1527)	0.126
Particle size				
VLDL	nm	41.8 (41.6, 41.9)	41.8 (41.7, 42.0)	0.310
LDL	nm	20.8 (20.6, 20.9)	20.7 (20.6, 20.9)	0.747
HDL	nm	8.25 (8.22, 8.28)	8.22 (8.18, 8.25)	0.153

Data are means (95% confidence interval). sdLDL (small dense LDL); LDL (Low Density Lipoprotein); VLDL (Very Low Density Lipoprotein); IDL (Intermediate Density Lipoprotein); HDL (High Density Lipoprotein); mVLDL (medium VLDL); sVLDL (small VLDL); ILDL (large LDL); mLDL (medium LDL); sLDL (small LDL); IHDL (large HDL); mHDL (medium HDL); sHDL (small HDL); Non-HDL (Non-HDL).




Figure S1: Effect of MetDiet and er-MetDiet+PA on Triglycerides and Remnant Lipoproteins at 6 and 12 months.
 LOG(Tg) (Log-transformed Triglycerides); VLDL-C (Very Low Density Lipoproteins Cholesterol); IDL-C (Intermediate Density Lipoproteins Cholesterol); MedDiet (Mediterranean Diet; er-MedDiet +PA (energy-reduced MedDiet and physical activity).




Figure S2: Effect of MetDiet and er-MetDiet+PA on HDL lipid composition and particle concentration at 6 and 12 months. HDL-C (High Density Lipoproteins Cholesterol); HDL-P (HDL Particle Number); HDL-Tg (HDL Triglycerides); IHDL-P (large HDL Particle Number); MedDiet (Mediterranean diet); er-MedDiet +PA (energy-reduced MedDiet and physical activity).




Figure S3: Effect of MetDiet and er-MetDiet+PA on VLDL advanced lipid profile results at 6 and 12 months. VLDL-C (Very Low Density Lipoproteins Cholesterol); VLDL-P (VLDL Particle Number); MedDiet (Mediterranean diet); er-MedDiet +PA (energy-reduced MedDiet and physical activity).




Figure S4: Effect of MetDiet and er-MetDiet+PA on LDL lipid composition and particle concentration at 6 and 12 months. LDL-C (Low Density Lipoproteins Cholesterol); LDL-P (LDL Particle Number); LDL-Tg (LDL Triglycerides); ILDL-P (large LDL Particle Number); MedDiet (Mediterranean diet); er-MedDiet +PA (energy-reduced MedDiet and physical activity).

Table S2: Effects of MedDiet and er-MedDiet+PA based intervention on lipid and anthropometric variables observed at 6 and 12 months in women.

	Time effect (Control effect*)				Interaction group and time (Intervention vs. Control effect**)				
	6 months		12 months		6 months		12 months		
	Coefficient [95%CI]	P value	Coefficient [95%CI]	P value	Coefficient [95%CI]	P value	Coefficient [95%CI]	P value	
Cholesterol	Body Mass Index (kg/m ²)	-0.53[-0.92;-0.15]	<0.01	-0.71[-1.1;-0.33]	<0.01	-1.62[-2.15;-1.08]	<0.01	-1.41[-1.95;-0.87]	<0.01
	Waist circumference (cm)	-2.77[-4.42;-1.12]	<0.01	-2.01[-3.67;-0.36]	0.017	-1.81[-4.11;0.5]	0.125	-2.11[-4.43;0.21]	0.074
	LDL (mmol/L)	-0.06[-0.29;0.18]	0.639	-0.28[-0.52;-0.05]	0.019	0.1[-0.22;0.43]	0.537	0.34[0.01;0.66]	0.045
	sdLDL (mmol/L)	-0.11[-0.29;0.07]	0.242	-0.17[-0.36;0.03]	0.089	-0.17[-0.42;0.08]	0.192	-0.03[-0.3;0.24]	0.839
	HDL (mmol/L)	0.05[-0.01;0.11]	0.078	0.01[-0.04;0.07]	0.65	-0.04[-0.12;0.04]	0.346	0.07[-0.01;0.15]	0.108
	Non-HDL (mmol/L)	-0.12[-0.46;0.22]	0.494	-0.54[-0.9;-0.18]	<0.01	0.29[-0.18;0.77]	0.228	0.8[0.27;1.32]	<0.01
Triglycerides	IDL (mg/dL)	-2.59[-7.82;2.65]	0.333	-3.74[-9.34;1.85]	0.189	0.47[-6.93;7.87]	0.901	-3.22[-11.79;5.35]	0.462
	VLDL (mg/dL)	-6.86[-16.86;3.15]	0.179	-8.59[-19.27;2.08]	0.115	3.05[-11.07;17.18]	0.672	-8.86[-25.22;7.51]	0.289
	VLDL+IDL (mg/dL)	-9.44[-23.16;4.28]	0.177	-12.34[-26.98;2.31]	0.099	3.52[-15.85;22.9]	0.722	-12.07[-34.52;10.37]	0.292
	LOG(Tg (mmol/L))	-0.12[-0.24;0]	0.049	-0.06[-0.17;0.06]	0.357	0.01[-0.15;0.18]	0.875	-0.06[-0.22;0.11]	0.49
	LDL (mg/dL)	-1.4[-7.03;4.23]	0.626	-3.25[-9.25;2.76]	0.289	-1.2[-9.15;6.74]	0.767	-4.25[-13.45;4.96]	0.366
	HDL (mg/dL)	-7.36[-15.74;1.02]	0.085	-1.2[-10.17;7.76]	0.793	2.41[-9.43;14.25]	0.69	-7.27[-21.05;6.52]	0.301
Particle number	IDL (mg/dL)	-2.03[-6.11;2.04]	0.329	-2.2[-6.56;2.15]	0.321	0.44[-5.32;6.19]	0.882	-4[-10.66;2.67]	0.24
	VLDL (mg/dL)	-24.59[-56.15;6.96]	0.127	-27.26[-61.27;6.75]	0.116	25.38[-19.22;69.97]	0.265	-14.64[-67.44;38.16]	0.587
	LDL (nmol/L)	-36.98[-327.12;253.16]	0.803	-247.26[-556.99;62.47]	0.118	45.04[-364.73;454.8]	0.829	37.41[-437.26;512.08]	0.877
	ILDL (μmol/L)	19.5[-13.81;52.8]	0.251	-5.54[-41.1;30.01]	0.76	-4.7[-51.73;42.34]	0.845	2.51[-51.98;57]	0.928
	sLDL (nmol/L)	-65.28[-211.74;81.17]	0.382	-175.43[-334.41;-16.44]	0.031	74.91[-132.19;282.02]	0.478	78.19[-171.01;327.4]	0.539
	HDL (μmol/L)	-5.65[-11.72;0.42]	0.068	0.02[-6.46;6.5]	0.995	4.17[-4.4;12.74]	0.34	-1.59[-11.52;8.34]	0.754
Particle size	IHDL (μmol/L)	-0.03[-0.08;0.02]	0.252	-0.01[-0.07;0.04]	0.616	0.02[-0.05;0.09]	0.535	-0.02[-0.1;0.06]	0.658
	sHDL (μmol/L)	-3.98[-8.26;0.3]	0.068	0.25[-4.32;4.82]	0.915	2.46[-3.58;8.5]	0.425	-2.43[-9.43;4.57]	0.496
	VLDL (nmol/L)	-21.53[-48.06;5]	0.112	-24.24[-52.8;4.32]	0.096	19.76[-17.73;57.25]	0.302	-13.84[-58.1;30.41]	0.54
	IVLDL (nmol/L)	-0.31[-0.87;0.25]	0.272	-0.28[-0.88;0.32]	0.365	0.28[-0.5;1.07]	0.48	-0.49[-1.42;0.44]	0.302
	sVLDL (nmol/L)	-20.74[-45.3;3.82]	0.098	-22.83[-49.31;3.65]	0.091	19.36[-15.35;54.08]	0.274	-11.89[-53;29.22]	0.571
	VLDL (nm)	0.22[-0.06;0.5]	0.13	0.27[-0.04;0.58]	0.083	-0.18[-0.58;0.22]	0.376	0.16[-0.32;0.63]	0.518
	LDL (nm)	0.18[-0.08;0.44]	0.164	0.3[0.02;0.58]	0.036	-0.11[-0.47;0.26]	0.565	-0.11[-0.55;0.32]	0.609
	HDL (nm)	0.01[-0.03;0.04]	0.791	0[-0.05;0.04]	0.876	0.02[-0.03;0.08]	0.386	0.05[-0.01;0.12]	0.109

LDL (Low Density Lipoprotein); sdLDL (small dense LDL); HDL (High Density Lipoprotein); Non-HDL (Non-High-Density Lipoprotein); IDL (Intermediate Density Lipoprotein); VLDL (Very Low-Density Lipoprotein); VLDL+IDL (Remnant Lipoproteins); Tg (Triglycerides); ILDL (large LDL); sLDL (small LDL); IHDL (large HDL); sHDL (small HDL); IVLDL (large VLDL); sVLDL (small VLDL); [IC95%] (95% confidence interval). Significant values are indicated with bold lettering. Data were analyzed by linear mixed models with intervention group, time (baseline, 6 and 12 months), interaction of group and time, and adjusted by age, the administration of lipid-lowering treatments, and smoking status. * Time effect: can be interpreted as the effect observed in the Control group. ** Interaction group and time: can be interpreted as the additional effect of the intervention group compared to the control group.

Table S3: Effects of MedDiet and er-MedDiet+PA based intervention on lipid and anthropometric variables observed at 6 and 12 months in men.

	Time effect (Control effect*)				Interaction group and time (Intervention vs. Control effect**)				
	6 months		12 months		6 months		12 months		
	Coefficient [95%CI]	P value	Coefficient [95%CI]	P value	Coefficient [95%CI]	P value	Coefficient [95%CI]	P value	
Body Mass Index (kg/m2)	-0.63[-0.98;-0.27]	<0.01	-0.52[-0.88;-0.16]	<0.01	-1.3[-1.8;-0.8]	<0.01	-1.43[-1.94;-0.92]	<0.01	
Waist circumference (cm)	-1.2[-2.48;0.08]	0.067	-2.43[-3.75;-1.11]	<0.01	-4.02[-5.83;-2.21]	<0.01	-2.18[-4.02;-0.33]	0.021	
Cholesterol	LDL (mmol/L)	-0.14[-0.36;0.07]	0.186	-0.24[-0.46;-0.01]	0.037	-0.03[-0.33;0.27]	0.838	0.12[-0.18;0.42]	0.447
	sdLDL (mmol/L)	-0.1[-0.26;0.06]	0.23	-0.09[-0.27;0.08]	0.305	-0.25[-0.47;-0.02]	0.03	-0.27[-0.52;-0.02]	0.031
	HDL (mmol/L)	0.04[-0.03;0.1]	0.246	0.02[-0.05;0.09]	0.537	0.11[0.02;0.2]	0.019	0.14[0.04;0.23]	<0.01
	Non-HDL (mmol/L)	-0.08[-0.39;0.23]	0.597	-0.21[-0.56;0.13]	0.229	-0.14[-0.58;0.3]	0.531	0.32[-0.19;0.83]	0.22
	IDL (mg/dL)	-2.04[-4.27;0.2]	0.074	-1.97[-4.61;0.67]	0.145	-1.79[-5.2;1.61]	0.302	-0.85[-5.49;3.8]	0.721
	VLDL (mg/dL)	-4.03[-10.65;2.6]	0.234	-1.65[-9.5;6.19]	0.679	-7.3[-17.42;2.82]	0.158	-13.18[-27.02;0.66]	0.062
	VLDL+IDL (mg/dL)	-6.06[-14.47;2.34]	0.157	-3.64[-13.59;6.31]	0.474	-9.16[-22.36;7]	0.162	-14.02[-31.55;3.51]	0.117
Triglycerides	LOG(Tg (mmol/L))	-0.21[-0.34;-0.08]	<0.01	-0.07[-0.21;0.07]	0.321	-0.12[-0.31;0.06]	0.198	-0.24[-0.43;-0.05]	0.014
	LDL (mg/dL)	-1.99[-4.95;0.97]	0.187	-1.87[-5.35;1.6]	0.291	-2.18[-6.68;2.31]	0.34	-1.92[-8;4.17]	0.537
	HDL (mg/dL)	-2.26[-6.57;2.04]	0.302	-0.66[-5.58;4.26]	0.792	-3.77[-10.15;2.62]	0.247	-6.02[-14.46;2.43]	0.163
	IDL (mg/dL)	-1.61[-3.48;0.25]	0.09	-1.39[-3.6;0.81]	0.216	-1.55[-4.4;1.29]	0.284	-0.98[-4.87;2.9]	0.62
	VLDL (mg/dL)	-9.05[-36.42;18.33]	0.517	-6.95[-39.29;25.38]	0.673	-35.85[-77.58;5.87]	0.092	-66.91[-123.79;-10.02]	0.021
Particle number	LDL (nmol/L)	70.12[-89.84;230.08]	0.39	-39.2[-226.51;148.11]	0.682	-171.03[-413.41;71.34]	0.167	-86.08[-413.05;240.9]	0.606
	ILDL (μmol/L)	17.25[-0.35;34.85]	0.055	11.03[-9.76;31.83]	0.298	-2.65[-29.48;24.18]	0.847	2.05[-34.53;38.63]	0.913
	sLDL (nmol/L)	50.44[-67.52;168.4]	0.402	-24.94[-160.4;110.52]	0.718	-160.8[-337.92;16.32]	0.075	-104.49[-337.11;128.13]	0.379
	HDL (μmol/L)	-1.43[-3.8;0.94]	0.236	-0.32[-3.1;2.45]	0.819	1.64[-1.95;5.23]	0.372	0.18[-4.68;5.05]	0.941
	IHDL (μmol/L)	-0.01[-0.04;0.02]	0.47	-0.01[-0.05;0.03]	0.597	0.02[-0.03;0.07]	0.428	-0.02[-0.08;0.05]	0.608
	sHDL (μmol/L)	-0.8[-2.98;1.38]	0.471	0.14[-2.43;2.71]	0.914	0.36[-2.96;3.68]	0.83	0.25[-4.27;4.76]	0.914
	VLDL (nmol/L)	-7.28[-25.01;10.46]	0.421	-4.76[-25.77;16.25]	0.657	-17.39[-45.21;10.44]	0.221	-28.53[-67.24;10.18]	0.149
	IVLDL (nmol/L)	-0.07[-0.43;0.29]	0.706	0[-0.43;0.43]	0.99	-0.57[-1.12;-0.01]	0.046	-0.97[-1.73;-0.21]	0.013
	sVLDL (nmol/L)	-5.76[-25.03;13.51]	0.558	-4.1[-26.87;18.67]	0.724	-7.66[-37.03;21.71]	0.609	-7.67[-47.73;32.38]	0.707
Particle size	VLDL (nm)	-0.04[-0.22;0.14]	0.652	-0.01[-0.22;0.2]	0.926	0.18[-0.1;0.46]	0.212	0.27[-0.09;0.63]	0.143
	LDL (nm)	0.01[-0.21;0.24]	0.901	0.05[-0.21;0.31]	0.72	0.24[-0.1;0.58]	0.171	0.15[-0.3;0.6]	0.517
	HDL (nm)	0[-0.04;0.03]	0.822	-0.02[-0.06;0.02]	0.37	-0.01[-0.07;0.05]	0.641	0.02[-0.06;0.1]	0.586

LDL (Low Density Lipoprotein); sdLDL (small dense LDL); HDL (High Density Lipoprotein); Non-HDL (Non-High-Density Lipoprotein); IDL (Intermediate Density Lipoprotein); VLDL (Very Low-Density Lipoprotein); VLDL+IDL (Remnant Lipoproteins); Tg (Triglycerides); ILDL (large LDL); sLDL (small LDL); IHDL (large HDL); sHDL (small HDL); IVLDL (large VLDL); sVLDL (small VLDL); [IC95%] (95% confidence interval). Significant values are indicated with bold lettering. Data were analyzed by linear mixed models with intervention group, time (baseline, 6 and 12 months), interaction of group and time, and adjusted by age, the administration of lipid-lowering treatments, and smoking status. * Time effect: can be interpreted as the effect observed in the Control group. ** Interaction group and time: can be interpreted as the additional effect of the intervention group compared to the control group.




Figure S5: Trial flow chart.

MedDiet (Mediterranean diet); er-MedDiet +PA (energy-reduced MedDiet and physical activity).